TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,206,338 | -46.4% | 246,794 | -7.9% | 0.00% | – |
| Q2 2023 | $4,117,479 | -63.2% | 268,065 | -46.1% | 0.00% | -100.0% |
| Q1 2023 | $11,180,364 | +384.1% | 497,126 | +352.7% | 0.00% | – |
| Q4 2022 | $2,309,283 | -41.3% | 109,809 | -31.3% | 0.00% | – |
| Q3 2022 | $3,937,000 | +91.6% | 159,774 | +88.4% | 0.00% | – |
| Q2 2022 | $2,055,000 | -42.5% | 84,806 | -38.9% | 0.00% | – |
| Q1 2022 | $3,575,000 | -70.6% | 138,728 | -64.6% | 0.00% | – |
| Q4 2021 | $12,166,000 | +122.7% | 391,952 | +74.0% | 0.00% | – |
| Q3 2021 | $5,464,000 | +107.8% | 225,289 | +25.0% | 0.00% | – |
| Q2 2021 | $2,629,000 | +0.3% | 180,174 | +71.6% | 0.00% | – |
| Q1 2021 | $2,622,000 | -75.2% | 104,998 | -72.9% | 0.00% | -100.0% |
| Q4 2020 | $10,562,000 | – | 387,528 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |